Patents by Inventor Onyx Therapeutics

Onyx Therapeutics has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130324459
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: March 12, 2013
    Publication date: December 5, 2013
    Applicant: ONYX THERAPEUTICS, INC.
    Inventor: Onyx Therapeutics, Inc.
  • Publication number: 20130150290
    Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.
    Type: Application
    Filed: February 1, 2013
    Publication date: June 13, 2013
    Applicant: Onyx Therapeutics, Inc.
    Inventor: Onyx Therapeutics, Inc.
  • Publication number: 20130150289
    Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.
    Type: Application
    Filed: February 1, 2013
    Publication date: June 13, 2013
    Applicant: Onyx Therapeutics, Inc.
    Inventor: Onyx Therapeutics, Inc.
  • Publication number: 20130130968
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
    Type: Application
    Filed: January 8, 2013
    Publication date: May 23, 2013
    Applicant: ONYX THERAPEUTICS, INC.
    Inventor: Onyx Therapeutics
  • Publication number: 20130053303
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 28, 2013
    Applicant: Onyx Therapeutics, Inc.
    Inventor: Onyx Therapeutics, Inc.
  • Publication number: 20130041008
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 14, 2013
    Applicant: ONYX THERAPEUTICS, INC.
    Inventor: Onyx therapeutics, Inc.
  • Publication number: 20130035297
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 7, 2013
    Applicant: ONYX THERAPEUTICS, INC.
    Inventor: Onyx therapeutics, Inc.